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background:   In the PLATO study, ticagrelor was unexpectedly associated with fewer deaths following pulmonary infections and sepsis. 
The risk of myocardial infarction or stroke is greatly increased following bacteremia, which can create an inflammatory environment 
associated with thrombotic changes in the fibrin network. We hypothesized that ticagrelor modulates fibrin-related thrombosis risk following 
bacteremia and therefore investigated whether bacterial endotoxemia affects clot structure and whether this can be reduced by ticagrelor in 
an experimental human model.
methods:  Thirty healthy volunteers were randomized to ticagrelor 90 mg bd (n=10), clopidogrel 75 mg od (n=10) or no antiplatelet 
medications (controls; n=10) for one week. E. coli endotoxin (lipopolysaccharide, LPS) 2 ng/kg was then administered intravenously. Blood 
was sampled pre-treatment, after treatment and at 6 and 24 hours post-LPS. Plasma fibrin clot structure was investigated ex vivo using a 
validated turbidimetric assay and results confirmed by scanning electron microscopy. Clot density and fibrin fiber diameter were assessed 
using ImageJ software.
Results:   In the control group, clot density increased from 65% at baseline to 70% (p<0.05) 6 hours after LPS administration. Ticagrelor 
attenuated this increase: fibrin clot density was significantly lower in the ticagrelor group compared to the control group (65% vs. 70%; 
p<0.05) at 6 hours. In the control group, fibrin fiber diameter significantly decreased from 88 nM to 73 nM (p<0.05) 6 hours after LPS 
administration. Ticagrelor also attenuated this change: fiber diameter was significantly greater in the ticagrelor group compared to the 
control group (90 nM vs. 73 nM; p<0.01) at 6 hours. Clopidogrel did not have a significant effect on fibrin clot density or fiber diameter.
conclusion:  To our knowledge, this is the first study to show that ticagrelor attenuates endotoxemia-induced prothrombotic changes in 
fibrin clot structure. This provides a potential mechanism whereby ticagrelor reduces the risk of cardiovascular events following pulmonary 
infection and sepsis.
